RemeGen Co. Ltd. Class H ( (HK:9995) ) has provided an update.
RemeGen Co., Ltd. held its 2025 second extraordinary general meeting (EGM) on April 2, 2025, where shareholders approved the appointment of Mr. Wen Qingkai as an executive director and member of the Strategy Committee. This appointment is expected to enhance the company’s strategic direction and governance, potentially impacting its operational effectiveness and stakeholder confidence.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, focusing on the biotechnology industry. The company is involved in the development and commercialization of innovative biopharmaceuticals, with a market focus on addressing unmet medical needs.
YTD Price Performance: 81.60%
Average Trading Volume: 3,927,131
Technical Sentiment Signal: Hold
Current Market Cap: HK$19.92B
Find detailed analytics on 9995 stock on TipRanks’ Stock Analysis page.